#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acquired haemophilia Cutaneous T-cell lymphoma refractory Ataxia telangiectasia Chronic lymphocytic leukaemia Colorectal adenocarcinoma Malignant neoplasm of choroid Leukodystrophy Hepatic angiosarcoma Retinoblastoma Fms-like tyrosine kinase 3 positive Exudative retinopathy Pemphigoid Myelodysplastic syndrome High-grade B-cell lymphoma Cutaneous T-cell lymphoma More trials…

    Learn about Rare Diseases

    Metachromatic leukodystrophy – Basic Information Waldenstrom’s macroglobulinaemia – Diagnostics Piriformis syndrome – Treatment Congenital hypotransferrinaemia Ehlers-Danlos syndrome – Trials in Disease Loeys-Dietz syndrome – Basic Information Cystic fibrosis Mastocytosis Advanced systemic mastocytosis Rhabdomyosarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bi 690517 Lisocabtagene Maraleucel YL201 SOFOSBUVIR Nitrofurantoin Sirolimus ALLERGEN EXTRACTS Litenimod Sodium Abc-16F-116 Altizide Crovalimab Bomedemstat Phenylalanine TETANUS TOXOID Nortriptyline Hydrochloride Travoprost Immunostimulants Axicabtagene Ciloleucel Dexpanthenol Rifaximin More therapies…

    Learn about Your Condition

    Leukocyte adhesion deficiency Bronchopulmonary dysplasia Neuromyopathy Angiosarcoma Tuberculosis Nicotine dependence Venous thrombosis limb Pyoderma Leiomyosarcoma metastatic Normal pressure hydrocephalus Microvillous inclusion disease Skin bacterial infection Renal cancer recurrent Merycism Tertiary adrenal insufficiency More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Jagiellońskie Centrum Innowacji Sp. z o.o.

Jagiellońskie Centrum Innowacji Sp. z o.o.

Ul. Profesora Michala Bobrzynskiego 14, Cracow, 30-348, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Pneumococcal Polysaccharide Serotype 19A Conjugated To Crm197
    • Pneumococcal Polysaccharide Serotype 22F Conjugated To Crm197
    • Pneumococcal Polysaccharide Serotype 3 Conjugated To Crm197
    Belgium Czechia Estonia Finland Germany Greece +3

  • Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Sodium Chloride Solution 0.9%
    Finland Germany The Netherlands Poland Sweden

  • Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid
    • N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
    • Neisseria Meningitidis Group A Polysaccharide Conjugated To Tetanus Toxoid Carrier Protein
    Czechia Denmark Finland Germany Poland Romania

  • Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

    Not recruiting

    3 1
    Investigated Diseases:
    • Neurodermatitis
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    Austria Bulgaria France Germany Italy The Netherlands +1

  • Study of PF-06821497 with Enzalutamide for Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Dexamethasone
    • Docetaxel
    Czechia France Germany Greece Hungary Italy +5

  • Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer metastatic
    Investigated Drugs:
    • Pf-07220060 Monohydrate
    • Everolimus
    • Exemestane
    Belgium Bulgaria Czechia Denmark Finland France +8

  • Study of N-Acetyl-GED-0507-34-LEVO 5% gel applied daily for 12 weeks in patients with acne vulgaris

    Not recruiting

    3 1
    Investigated Drugs:
    • (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
    Italy Poland Spain

  • Title: Long-term safety study of N-Acetyl-GED-0507-34-LEVO gel 5% applied to the skin for patients with acne vulgaris

    Not recruiting

    3 1 1
    Investigated Drugs:
    • (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
    Italy Poland Spain

  • Study on the Safety and Effects of Livmoniplimab and Budigalimab in Patients with Advanced or Metastatic Solid Tumors

    Not recruiting

    1 1 1
    Investigated Drugs:
    • Budigalimab
    • Livmoniplimab
    Belgium France Germany Italy Poland Spain

  • Study on the Safety and Effects of IMG-007 for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Img-007
    Germany Poland
Previous Page
1 2 3 4
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!